In the case of BCR::ABL1-mediated CML, it is clear that acquisition of secondary mutations in ABL kinase domain are one of the most prevalent drug resistance mechanism (Figure 2). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.